Top-News

BioMarin Pharmaceutical Aktie News

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN Branche:  Biotechnologie Land:  USA
53,81 $
-0,50 $
-0,92%
46,175 € 04.12.25
Depot/Watchlist
Marktkapitalisierung *
9,04 Mrd. €
Streubesitz
-
KGV
30,29
Index-Zuordnung
Nasdaq Composite Index

BioMarin Pharmaceutical News

11.11.25 - PR Newswire
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England PR Newswire
29.10.25 - PR Newswire
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-​pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with ...
27.10.25 - PR Newswire
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update PR Newswire
22.10.25 - PR Newswire
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET PR Newswire
08.09.25 - PR Newswire
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting PR Newswire
06.09.25 - PR Newswire
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of ...
27.08.25 - PR Newswire
BioMarin to Participate in Upcoming Investor Conferences
BioMarin to Participate in Upcoming Investor Conferences PR Newswire
04.08.25 - PR Newswire
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS PR Newswire
01.08.25 - PR Newswire
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
BioMarin Announces Appointment of Ian T. Clark to Board of Directors PR Newswire
22.07.25 - PR Newswire
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET PR Newswire
01.07.25 - PR Newswire
BioMarin Announces Completion of Acquisition of Inozyme
BioMarin Announces Completion of Acquisition of Inozyme PR Newswire
24.06.25 - PR Newswire
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-​rvox) at International Society on Thrombosis ...
16.05.25 - PR Newswire
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma PR Newswire
12.05.25 - PR Newswire
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings PR Newswire
01.05.25 - PR Newswire
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance PR Newswire
17.04.25 - PR Newswire
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET PR Newswire
02.04.25 - PR Newswire
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria PR Newswire
20.03.25 - PR Newswire
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-​World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with ...
25.02.25 - PR Newswire
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA PR Newswire
24.02.25 - PR Newswire
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »